Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Focal adhesion (mmu04510)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
1110001D
15Rik
KLA  ATP  ATP+KLA
 NM_026763 RIKEN cDNA 1110001D15 gene (1110001D15Rik), mRNA [NM_026763] KLA 1.01 1.00 1.05 1.06 1.06 1.07 1.04
ATP 1.03 1.02 1.06 1.03 1.09 1.11 .95
KLA/ATP 1.04 1.02 1.07 1.05 1.01 1.06 1.04
2900073G
15Rik
KLA  ATP  ATP+KLA
 NM_026064 RIKEN cDNA 2900073G15 gene (2900073G15Rik), mRNA [NM_026064] KLA 1.50 1.46 1.64 1.51 1.69 1.72 1.15
ATP 1.05 1.10 1.24 1.39 1.23 1.13 1.03
KLA/ATP 1.50 1.60 1.64 1.71 1.36 1.21 1.11
AK044510
KLA  ATP  ATP+KLA
 AK044510 adult retina cDNA, RIKEN full-length enriched library, clone:A930017M14 product:laminin, alpha 1, full insert sequence. [AK044510] KLA .96 1.07 1.03 1.05 1.00 1.06 1.16
ATP 1.04 1.04 1.04 1.04 1.05 1.08 1.01
KLA/ATP .96 1.08 1.07 1.10 1.12 1.08 1.01
AK044953
KLA  ATP  ATP+KLA
 AK044953 9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130015K01 product:unclassifiable, full insert sequence. [AK044953] KLA .54 .53 .47 .57 .61 .59 .60
ATP 1.02 .94 1.06 .95 .53 .55 .73
KLA/ATP .54 .47 .60 .67 .66 .49 .50
AK050363
KLA  ATP  ATP+KLA
 AK050363 adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730040N22 product:unclassifiable, full insert sequence. [AK050363] KLA 1.00 .98 1.02 1.02 1.02 .92 .96
ATP .98 1.03 .93 .98 .96 1.02 .99
KLA/ATP 1.03 .96 .96 .95 1.02 .93 1.04
Actb
KLA  ATP  ATP+KLA
 BC016624 cDNA clone IMAGE:4501052 [BC016624] KLA 1.20 1.20 1.19 1.73 1.83 2.52 1.70
ATP 1.04 1.01 1.03 .92 1.07 .66 .91
KLA/ATP 1.34 1.40 1.69 1.28 1.27 1.19 1.06
Actb
KLA  ATP  ATP+KLA
 NM_007393 actin, beta, cytoplasmic (Actb), mRNA [NM_007393] KLA 1.58 1.64 1.59 2.02 2.03 3.04 1.75
ATP 1.00 .95 1.26 1.18 1.33 .86 .91
KLA/ATP 1.52 1.75 2.42 1.92 2.17 1.54 1.28
Actg1
KLA  ATP  ATP+KLA
 NM_009609 actin, gamma, cytoplasmic 1 (Actg1), mRNA [NM_009609] KLA 1.02 1.03 1.34 1.07 1.49 1.58 .71
ATP 1.07 1.24 .76 .76 .63 .46 .78
KLA/ATP 1.20 1.30 .75 .82 .60 .53 .55
Actn1
KLA  ATP  ATP+KLA
 NM_134156 actinin, alpha 1 (Actn1), mRNA [NM_134156] KLA 1.33 1.42 1.46 1.16 1.18 .69 .54
ATP 1.06 1.13 .67 1.15 .95 .99 1.46
KLA/ATP 1.66 1.64 .81 1.55 .82 .78 .76
Actn2
KLA  ATP  ATP+KLA
 NM_033268 actinin alpha 2 (Actn2), mRNA [NM_033268] KLA 1.03 .94 1.02 1.05 1.02 1.06 1.11
ATP 1.04 .98 1.07 .99 1.10 1.03 1.02
KLA/ATP 1.06 1.03 .99 1.08 1.01 1.05 .98
Actn3
KLA  ATP  ATP+KLA
 NM_013456 actinin alpha 3 (Actn3), mRNA [NM_013456] KLA .97 .98 .98 .94 1.03 .96 1.07
ATP .95 .95 1.02 .98 .94 .95 1.01
KLA/ATP 1.05 1.03 .94 1.03 1.03 1.00 .95
Actn4
KLA  ATP  ATP+KLA
 NM_021895 actinin alpha 4 (Actn4), mRNA [NM_021895] KLA .78 .77 .75 .74 .58 .51 .65
ATP 1.03 1.03 1.21 1.14 1.50 1.30 1.09
KLA/ATP .78 .85 .96 .84 1.09 1.12 .97
Akt1
KLA  ATP  ATP+KLA
 NM_009652 thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] KLA .80 .80 .75 .75 .71 .70 .82
ATP 1.00 1.02 .76 .85 .76 .68 .84
KLA/ATP .82 .80 .64 .68 .67 .61 .72
Akt2
KLA  ATP  ATP+KLA
 NM_007434 thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] KLA 1.45 1.49 1.81 1.61 1.83 1.17 .92
ATP 1.12 1.12 1.00 1.28 1.20 .94 1.06
KLA/ATP 1.48 1.70 1.69 1.58 1.57 1.32 1.27
Akt3
KLA  ATP  ATP+KLA
 NM_011785 thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] KLA 3.42 3.45 5.31 5.16 4.65 3.80 2.12
ATP 1.12 1.22 1.10 1.37 1.02 1.11 1.56
KLA/ATP 3.72 4.17 4.62 4.64 2.74 2.05 3.82
Arhgap5
KLA  ATP  ATP+KLA
 AK039081 adult male hypothalamus cDNA, RIKEN full-length enriched library, clone:A230093J24 product:unclassifiable, full insert sequence. [AK039081] KLA .95 .99 .86 .90 .95 .92 .87
ATP 1.05 1.06 1.03 .86 .93 .96 .96
KLA/ATP .90 .90 .92 .83 .92 .83 .86
Arhgap5
KLA  ATP  ATP+KLA
 NM_009706 Rho GTPase activating protein 5 (Arhgap5), mRNA [NM_009706] KLA .54 .52 .50 .51 .38 .37 .75
ATP 1.04 .78 .87 .64 1.25 1.16 1.29
KLA/ATP .49 .47 .51 .45 .81 .67 .92
BC010335
KLA  ATP  ATP+KLA
 BC010335 fibronectin 1, mRNA (cDNA clone IMAGE:3156499), **** WARNING: chimeric clone ****. [BC010335] KLA .94 .88 1.01 .99 .95 .95 1.07
ATP 1.06 .98 1.20 1.30 1.07 .97 .97
KLA/ATP .93 1.00 1.07 1.20 1.02 .96 .94
BG242006
KLA  ATP  ATP+KLA
 BG242006 gb|602354740F1 NCI_CGAP_Mam1 Mus musculus cDNA clone IMAGE:4483064 5. [BG242006] KLA 2.25 2.23 2.26 2.70 2.56 2.67 1.45
ATP .92 .87 1.11 .97 .99 .97 .72
KLA/ATP 1.91 2.04 2.51 2.08 1.99 1.15 .67
Bad
KLA  ATP  ATP+KLA
 AK029400 0 day neonate head cDNA, RIKEN full-length enriched library, clone:4833429M11 product:Bcl-associated death promoter, full insert sequence. [AK029400] KLA 1.15 1.22 1.26 1.31 1.40 1.67 1.59
ATP .95 1.06 1.12 1.06 .78 .89 1.27
KLA/ATP 1.25 1.39 1.33 1.29 1.11 .91 1.38
Bcar1
KLA  ATP  ATP+KLA
 NM_009954 breast cancer anti-estrogen resistance 1 (Bcar1), mRNA [NM_009954] KLA .88 .87 .82 .88 1.06 1.12 1.70
ATP 1.04 1.05 1.00 1.27 1.34 1.62 1.34
KLA/ATP .95 .87 .87 .95 1.02 1.17 2.10
Bcl2
KLA  ATP  ATP+KLA
 NM_009741 B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 1, mRNA [NM_009741] KLA .30 .26 .25 .25 .34 .38 .26
ATP .97 .89 1.50 1.04 .99 .29 .52
KLA/ATP .28 .26 .40 .33 .62 .29 .12
Bcl2
KLA  ATP  ATP+KLA
 NM_177410 B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 2, mRNA [NM_177410] KLA .33 .33 .37 .42 .49 .46 .39
ATP 1.07 1.12 1.22 1.56 1.00 .38 .76
KLA/ATP .35 .34 .54 .89 .76 .36 .23
Birc2
KLA  ATP  ATP+KLA
 NM_007465 baculoviral IAP repeat-containing 2 (Birc2), mRNA [NM_007465] KLA 4.63 4.59 3.77 2.79 2.32 2.07 1.84
ATP .95 .88 .84 .92 .76 1.34 1.28
KLA/ATP 4.70 4.93 4.13 2.60 1.34 1.60 2.31
Birc3
KLA  ATP  ATP+KLA
 BC011338 baculoviral IAP repeat-containing 3, mRNA (cDNA clone MGC:18386 IMAGE:3661563), complete cds [BC011338] KLA 5.48 5.46 4.94 4.16 4.91 3.36 3.74
ATP 1.05 1.08 4.21 4.28 2.59 2.55 1.57
KLA/ATP 6.78 8.91 11.01 4.87 2.28 2.12 3.66
Birc3
KLA  ATP  ATP+KLA
 NM_007464 baculoviral IAP repeat-containing 3 (Birc3), mRNA [NM_007464] KLA 17.83 15.88 13.48 11.14 11.79 6.90 6.10
ATP 1.14 1.16 1.70 4.07 5.00 6.33 2.41
KLA/ATP 14.77 16.44 19.09 13.91 8.27 6.22 7.73
Braf
KLA  ATP  ATP+KLA
 NM_139294 Braf transforming gene (Braf), mRNA [NM_139294] KLA 1.52 1.57 1.55 1.33 1.83 1.52 1.60
ATP 1.08 1.17 1.02 1.37 .95 1.15 .95
KLA/ATP 1.64 1.69 1.39 1.51 1.04 1.31 1.26
Capn2
KLA  ATP  ATP+KLA
 NM_009794 calpain 2 (Capn2), mRNA [NM_009794] KLA .63 .65 .70 .57 .60 .61 .58
ATP 1.03 1.21 .78 .98 .82 .59 1.19
KLA/ATP .80 .71 .37 .54 .45 .46 1.05
Cav1
KLA  ATP  ATP+KLA
 NM_007616 caveolin, caveolae protein 1 (Cav1), mRNA [NM_007616] KLA 14.41 13.85 11.14 10.72 9.47 4.26 1.52
ATP 1.05 1.13 1.37 1.72 3.27 15.82 13.01
KLA/ATP 12.62 15.59 16.15 16.68 11.37 8.19 14.27
Cav2
KLA  ATP  ATP+KLA
 NM_016900 caveolin 2 (Cav2), mRNA [NM_016900] KLA 1.04 1.01 .95 .81 .55 .29 .40
ATP 1.08 1.17 1.18 1.18 1.02 .93 .74
KLA/ATP 1.04 1.08 .96 1.13 .62 .28 .57
Cav3
KLA  ATP  ATP+KLA
 NM_007617 caveolin 3 (Cav3), mRNA [NM_007617] KLA 1.01 1.05 1.01 1.08 .97 1.04 1.07
ATP 1.00 1.00 1.03 1.08 1.02 1.08 .98
KLA/ATP 1.05 .98 .83 1.14 1.09 1.10 1.00
Ccnd1
KLA  ATP  ATP+KLA
 S78355 gb|Cyl-1=cyclin D1 [mice, BALB/c, brain, mRNA, 3737 nt]. [S78355] KLA .24 .23 .23 .24 .29 .47 .17
ATP 1.02 1.02 .88 .80 .52 .10 .21
KLA/ATP .27 .23 .22 .24 .27 .25 .14
Ccnd2
KLA  ATP  ATP+KLA
 NM_009829 cyclin D2 (Ccnd2), mRNA [NM_009829] KLA 12.92 13.66 11.94 12.37 11.11 5.44 1.53
ATP .98 .75 .50 .57 1.24 2.83 .40
KLA/ATP 11.19 11.62 10.34 7.96 7.92 7.10 2.57
Ccnd3
KLA  ATP  ATP+KLA
 NM_007632 cyclin D3 (Ccnd3), transcript variant 1, mRNA [NM_007632] KLA .60 .65 .86 1.02 1.91 2.26 1.45
ATP 1.05 1.14 .89 1.20 .74 .76 .99
KLA/ATP .70 .67 .54 .83 .61 1.19 1.45
Cdc42
KLA  ATP  ATP+KLA
 NM_009861 cell division cycle 42 homolog (S. cerevisiae) (Cdc42), mRNA [NM_009861] KLA 1.04 1.01 1.02 1.04 1.12 1.21 1.12
ATP 1.07 1.10 1.04 1.06 1.02 .95 1.14
KLA/ATP .94 1.04 1.01 .97 .95 1.02 1.25
Chad
KLA  ATP  ATP+KLA
 NM_007689 chondroadherin (Chad), mRNA [NM_007689] KLA 1.34 1.32 1.36 1.26 1.27 1.30 1.31
ATP 1.03 .94 1.16 1.08 1.12 1.37 1.26
KLA/ATP 1.36 1.44 1.52 1.57 1.32 1.42 1.56
Col11a1
KLA  ATP  ATP+KLA
 AK021265 12 days embryo spinal cord cDNA, RIKEN full-length enriched library, clone:C530001D20 product:unclassifiable, full insert sequence. [AK021265] KLA 1.02 1.01 1.03 1.06 1.02 1.03 1.05
ATP .97 .92 1.02 .96 .93 1.11 1.00
KLA/ATP 1.01 .96 .97 1.00 1.04 .89 1.08
Col11a1
KLA  ATP  ATP+KLA
 NM_007729 collagen, type XI, alpha 1 (Col11a1), mRNA [NM_007729] KLA 1.06 1.06 1.10 1.05 1.07 1.01 1.09
ATP .97 .93 .95 1.03 .96 1.01 1.05
KLA/ATP 1.03 .98 1.02 1.02 .97 .99 1.05
Col11a2
KLA  ATP  ATP+KLA
 NM_009926 collagen, type XI, alpha 2 (Col11a2), mRNA [NM_009926] KLA 5.62 5.61 5.24 4.99 3.69 1.95 1.14
ATP .95 .95 1.17 1.59 1.73 1.28 1.12
KLA/ATP 5.25 5.62 6.37 5.73 4.79 2.22 1.39
Col1a1
KLA  ATP  ATP+KLA
 NM_007742 collagen, type I, alpha 1 (Col1a1), mRNA [NM_007742] KLA 1.13 1.10 1.22 1.18 1.04 1.15 1.09
ATP 1.03 1.00 1.34 1.48 1.11 1.13 1.11
KLA/ATP 1.13 1.29 1.47 1.77 1.38 1.33 1.13
Col1a2
KLA  ATP  ATP+KLA
 AK031577 13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030456A07 product:procollagen, type I, alpha 2, full insert sequence. [AK031577] KLA .98 1.03 1.02 1.01 1.03 1.01 .90
ATP .97 .96 .96 1.00 .92 1.00 1.00
KLA/ATP .97 1.00 1.02 1.06 .96 .98 1.00
Col1a2
KLA  ATP  ATP+KLA
 NM_007743 collagen, type I, alpha 2 (Col1a2), mRNA [NM_007743] KLA 1.25 1.20 1.58 1.41 1.32 1.51 1.08
ATP .92 .97 1.50 1.66 1.38 1.23 1.14
KLA/ATP 1.35 1.46 2.19 2.47 1.99 1.64 1.36
Col24a1
KLA  ATP  ATP+KLA
 NM_027770 collagen, type XXIV, alpha 1 (Col24a1), mRNA [NM_027770] KLA .96 1.03 .95 .99 1.01 1.02 .98
ATP .98 1.03 1.04 1.04 .95 .99 1.00
KLA/ATP 1.04 .98 1.01 .99 1.01 .93 .96
Col27a1
KLA  ATP  ATP+KLA
 AK076297 0 day neonate skin cDNA, RIKEN full-length enriched library, clone:4632427K15 product:procollagen, type XXVII, alpha 1, full insert sequence. [AK076297] KLA 1.19 1.39 1.10 1.06 1.01 1.04 .96
ATP 1.00 .99 1.02 .99 1.01 1.06 1.08
KLA/ATP 1.23 1.26 1.12 1.10 1.12 .95 1.03
Col27a1
KLA  ATP  ATP+KLA
 NM_025685 collagen, type XXVII, alpha 1 (Col27a1), mRNA [NM_025685] KLA 3.10 3.05 2.89 1.86 1.37 1.14 1.16
ATP 1.02 1.00 1.10 1.22 1.24 1.15 1.12
KLA/ATP 3.43 3.57 2.62 1.99 1.42 1.23 1.24
Col2a1
KLA  ATP  ATP+KLA
 AK053784 0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130308G17 product:unclassifiable, full insert sequence. [AK053784] KLA .95 .97 1.05 .93 .94 .94 .98
ATP .99 .91 .97 .87 .99 1.03 .93
KLA/ATP .95 1.05 .95 1.01 .97 .97 1.00
Col2a1
KLA  ATP  ATP+KLA
 NM_031163 collagen, type II, alpha 1 (Col2a1), transcript variant 1, mRNA [NM_031163] KLA 1.20 1.28 1.29 1.21 1.33 1.24 1.21
ATP .98 1.02 1.02 1.09 1.02 1.01 1.09
KLA/ATP 1.33 1.28 1.09 1.32 1.15 1.12 1.17
Col3a1
KLA  ATP  ATP+KLA
 AK031544 13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030449K06 product:PROCOLLAGEN, TYPE III, ALPHA 1 (FRAGMENT) homolog [Mus musculus], full insert sequence. [AK031544] KLA 1.04 .95 1.01 1.04 1.04 1.03 .97
ATP 1.00 .98 1.02 1.00 1.03 1.00 .98
KLA/ATP 1.11 1.03 1.05 .90 .95 1.01 .97
Col3a1
KLA  ATP  ATP+KLA
 NM_009930 collagen, type III, alpha 1 (Col3a1), mRNA [NM_009930] KLA 1.06 1.08 1.02 .99 1.02 1.03 .99
ATP .97 1.01 1.07 1.01 .92 .94 .99
KLA/ATP .97 .99 1.09 1.11 .98 1.00 1.02
Col4a1
KLA  ATP  ATP+KLA
 NM_009931 collagen, type IV, alpha 1 (Col4a1), mRNA [NM_009931] KLA 1.13 1.19 1.12 1.09 1.04 .89 .90
ATP 1.01 1.17 1.02 1.04 .91 .89 .97
KLA/ATP 1.14 1.24 1.03 1.15 .95 .86 1.01
Col4a2
KLA  ATP  ATP+KLA
 NM_009932 collagen, type IV, alpha 2 (Col4a2), mRNA [NM_009932] KLA 1.30 1.45 1.54 1.40 1.71 1.71 2.12
ATP 1.09 1.07 .98 1.03 .92 1.21 1.42
KLA/ATP 1.45 1.53 1.24 1.29 1.16 1.57 3.31
Col4a3
KLA  ATP  ATP+KLA
 NM_007734 collagen, type IV, alpha 3 (Col4a3), mRNA [NM_007734] KLA 1.09 1.11 1.12 1.10 1.05 1.06 1.04
ATP 1.02 1.03 1.01 .99 1.01 1.07 1.07
KLA/ATP 1.04 1.13 1.01 1.09 1.02 .98 1.01
Col4a4
KLA  ATP  ATP+KLA
 NM_007735 collagen, type IV, alpha 4 (Col4a4), mRNA [NM_007735] KLA 1.35 1.29 1.33 1.39 1.30 1.18 .98
ATP 1.14 1.08 1.30 1.54 1.54 1.34 .93
KLA/ATP 1.37 1.41 1.70 1.88 1.67 1.29 1.19
Col4a5
KLA  ATP  ATP+KLA
 NM_007736 collagen, type IV, alpha 5 (Col4a5), mRNA [NM_007736] KLA 1.00 .95 .95 .82 .72 .58 .70
ATP 1.05 1.18 .98 .88 .56 .53 .57
KLA/ATP 1.04 1.05 .83 .82 .58 .49 .61
Col4a6
KLA  ATP  ATP+KLA
 NM_053185 collagen, type IV, alpha 6 (Col4a6), mRNA [NM_053185] KLA 1.06 1.04 1.00 1.07 .94 .93 .94
ATP .97 .96 1.18 1.10 1.07 1.04 .86
KLA/ATP 1.00 1.05 1.22 1.06 1.12 1.02 .93
Col5a1
KLA  ATP  ATP+KLA
 NM_015734 collagen, type V, alpha 1 (Col5a1), mRNA [NM_015734] KLA 1.00 .99 1.07 1.01 1.03 1.01 1.10
ATP 1.02 .98 1.02 1.07 .96 1.01 1.09
KLA/ATP 1.03 1.01 1.08 1.08 1.01 1.09 1.08
Col5a2
KLA  ATP  ATP+KLA
 NM_007737 collagen, type V, alpha 2 (Col5a2), mRNA [NM_007737] KLA .96 1.01 1.12 1.03 .99 .98 .90
ATP .99 1.06 1.05 1.10 .90 .98 1.06
KLA/ATP .95 1.01 1.05 1.11 1.07 1.04 1.14
Col5a3
KLA  ATP  ATP+KLA
 NM_016919 collagen, type V, alpha 3 (Col5a3), mRNA [NM_016919] KLA 1.33 1.48 1.48 1.47 1.45 1.31 1.08
ATP 1.06 1.02 1.08 1.06 1.07 1.35 1.48
KLA/ATP 1.42 1.50 1.42 1.45 1.27 1.32 1.37
Col6a1
KLA  ATP  ATP+KLA
 NM_009933 collagen, type VI, alpha 1 (Col6a1), mRNA [NM_009933] KLA 1.08 1.12 1.29 1.16 1.17 .96 1.03
ATP 1.05 1.03 1.01 1.07 .98 .96 .88
KLA/ATP 1.16 1.18 .92 1.17 1.01 .98 .92
Col6a2
KLA  ATP  ATP+KLA
 AK044870 9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130009B12 product:procollagen, type VI, alpha 2, full insert sequence. [AK044870] KLA 1.06 1.00 .99 .96 .96 1.00 1.01
ATP .95 .95 .92 1.10 1.09 1.03 1.01
KLA/ATP 1.01 .97 .98 1.04 .98 1.04 .96
Col6a2
KLA  ATP  ATP+KLA
 NM_146007 collagen, type VI, alpha 2 (Col6a2), mRNA [NM_146007] KLA .94 1.06 1.00 1.07 1.05 1.04 1.00
ATP 1.01 .99 1.02 1.01 1.00 1.01 .98
KLA/ATP 1.01 .99 1.04 1.01 1.08 1.01 .95
Col6a3
KLA  ATP  ATP+KLA
 AF034136 collagen alpha3(VI) (Col6a3) mRNA, partial cds [AF034136] KLA .97 1.00 1.03 1.00 1.03 1.04 1.06
ATP 1.00 .93 1.00 1.01 1.07 .97 1.01
KLA/ATP 1.08 1.04 1.05 1.04 .99 1.10 1.02
Comp
KLA  ATP  ATP+KLA
 NM_016685 cartilage oligomeric matrix protein (Comp), mRNA [NM_016685] KLA 1.02 1.09 1.18 1.08 .96 1.12 .97
ATP .89 1.02 .97 .95 1.13 2.59 1.24
KLA/ATP 1.09 1.09 1.03 .98 1.60 2.02 1.15
Crk
KLA  ATP  ATP+KLA
 NM_133656 v-crk sarcoma virus CT10 oncogene homolog (avian) (Crk), mRNA [NM_133656] KLA 1.29 1.32 1.41 1.38 1.75 1.59 1.52
ATP 1.08 1.17 1.01 .93 1.27 2.11 1.70
KLA/ATP 1.37 1.49 1.14 1.09 1.21 1.69 2.32
Crkl
KLA  ATP  ATP+KLA
 NM_007764 v-crk sarcoma virus CT10 oncogene homolog (avian)-like (Crkl), mRNA [NM_007764] KLA 1.85 1.97 2.08 1.73 1.66 1.64 1.36
ATP .97 .94 .78 .74 1.46 1.89 1.46
KLA/ATP 1.92 1.88 1.18 1.44 1.67 2.65 2.72
Ctnnb1
KLA  ATP  ATP+KLA
 AK020013 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830416C23 product:catenin beta, full insert sequence. [AK020013] KLA 1.06 1.15 1.00 1.06 1.27 1.14 1.03
ATP .85 .57 1.74 3.36 4.13 2.19 1.55
KLA/ATP 1.12 .87 2.47 3.61 3.79 2.21 2.06
Ctnnb1
KLA  ATP  ATP+KLA
 NM_007614 catenin (cadherin associated protein), beta 1 (Ctnnb1), mRNA [NM_007614] KLA 1.02 1.07 1.13 1.03 1.04 .93 .96
ATP 1.12 1.14 .75 .77 .73 .72 1.52
KLA/ATP 1.18 1.17 .77 .85 .60 .59 1.35
Diap1
KLA  ATP  ATP+KLA
 BC070412 diaphanous homolog 1 (Drosophila), mRNA (cDNA clone MGC:86169 IMAGE:5705112), complete cds [BC070412] KLA .91 .97 .93 .75 .83 .85 1.02
ATP 1.08 1.18 1.07 1.07 1.12 1.11 1.15
KLA/ATP 1.01 1.00 .74 .83 .83 .94 1.09
Diap1
KLA  ATP  ATP+KLA
 NM_007858 diaphanous homolog 1 (Drosophila) (Diap1), mRNA [NM_007858] KLA 1.10 1.23 1.25 1.04 1.11 1.00 1.17
ATP 1.20 1.38 1.02 1.43 1.43 1.27 1.28
KLA/ATP 1.43 1.38 .88 1.30 1.04 1.18 1.56
Dock1
KLA  ATP  ATP+KLA
 AK163853 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130086K10 product:dedicator of cyto-kinesis 1, full insert sequence. [AK163853] KLA .94 .92 .94 .89 .75 .72 .75
ATP 1.04 1.01 .93 .84 .69 .63 1.16
KLA/ATP .84 .87 .76 .78 .71 .66 .65
Dock1
KLA  ATP  ATP+KLA
 NM_001033420 dedicator of cytokinesis 1 (Dock1), mRNA [NM_001033420] KLA 1.15 .95 .89 .75 .42 .19 .31
ATP 1.01 .83 .45 .41 .30 .17 .37
KLA/ATP .94 .85 .40 .24 .16 .15 .16
E330026B
02Rik
KLA  ATP  ATP+KLA
 NM_172927 RIKEN cDNA E330026B02 gene (E330026B02Rik), transcript variant 2, mRNA [NM_172927] KLA .94 .98 1.02 1.02 .97 1.05 .99
ATP .97 .94 .98 1.02 1.02 .99 1.02
KLA/ATP 1.01 .99 1.03 1.04 .96 .97 .94
Egf
KLA  ATP  ATP+KLA
 NM_010113 epidermal growth factor (Egf), mRNA [NM_010113] KLA .89 .90 .81 .83 .83 .86 .92
ATP 1.03 1.03 .95 .84 .67 .79 .88
KLA/ATP .86 .86 .77 .77 .69 .78 .83
Egfr
KLA  ATP  ATP+KLA
 NM_007912 epidermal growth factor receptor (Egfr), transcript variant 2, mRNA [NM_007912] KLA 1.10 1.07 1.14 1.11 1.08 1.03 .90
ATP .99 1.00 1.04 .98 .97 1.15 1.14
KLA/ATP 1.07 1.10 1.16 1.08 1.01 .97 .94
Egfr
KLA  ATP  ATP+KLA
 NM_207655 epidermal growth factor receptor (Egfr), transcript variant 1, mRNA [NM_207655] KLA 1.57 1.44 1.47 1.31 .96 .92 .76
ATP .97 .93 1.10 1.00 1.41 2.97 .86
KLA/ATP 1.44 1.50 1.61 1.30 1.14 1.21 .82
Elk1
KLA  ATP  ATP+KLA
 AK082260 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230030F12 product:ELK1, member of ETS oncogene family, full insert sequence. [AK082260] KLA 1.02 1.01 1.01 .97 1.00 1.03 1.06
ATP 1.02 1.07 1.06 1.03 1.02 1.02 1.00
KLA/ATP 1.08 .99 .97 1.01 1.02 1.06 .95
Erbb2
KLA  ATP  ATP+KLA
 NM_001003817 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (Erbb2), mRNA [NM_001003817] KLA 1.01 1.00 .98 1.01 .98 .99 .97
ATP .99 1.00 1.00 1.00 .96 .98 .99
KLA/ATP 1.00 1.01 1.01 1.02 .96 .98 .97
Figf
KLA  ATP  ATP+KLA
 NM_010216 c-fos induced growth factor (Figf), mRNA [NM_010216] KLA .92 .95 .93 .87 .82 .87 .77
ATP 1.03 1.04 1.06 .90 1.13 2.02 .78
KLA/ATP .92 .94 .97 .85 .97 1.10 .92
Flna
KLA  ATP  ATP+KLA
 AK044856 9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130008E07 product:hypothetical Calponin homology (CH) domain containing protein, full insert sequence. [AK044856] KLA .95 .95 1.00 .99 1.02 1.10 1.00
ATP .93 .94 1.02 1.08 1.04 1.01 .99
KLA/ATP 1.02 .98 .99 .98 1.02 1.08 1.02
Flna
KLA  ATP  ATP+KLA
 NM_010227 filamin, alpha (Flna), mRNA [NM_010227] KLA .90 .91 .92 .83 1.03 1.12 .82
ATP 1.02 1.06 .77 .69 .58 .69 .72
KLA/ATP .97 .90 .69 .66 .49 .59 .83
Flnb
KLA  ATP  ATP+KLA
 AK050046 adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730006K15 product:filamin, beta, full insert sequence. [AK050046] KLA 5.58 4.67 5.09 3.71 3.12 1.55 1.22
ATP .97 1.04 1.40 1.56 2.09 1.87 1.06
KLA/ATP 6.20 5.77 5.48 4.31 2.53 2.35 1.37
Flnb
KLA  ATP  ATP+KLA
 NM_134080 filamin, beta (Flnb), mRNA [NM_134080] KLA 8.86 8.95 10.89 9.75 10.94 7.28 1.54
ATP 1.03 1.08 1.17 1.39 1.82 2.72 1.01
KLA/ATP 8.89 10.37 11.36 10.83 7.90 5.59 3.36
Flnc
KLA  ATP  ATP+KLA
 AK051985 12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230030L22 product:weakly similar to CGABP260 ACTIN-BINDING DOMAIN (FRAGMENT) [Gallus gallus], full insert sequence. [AK051985] KLA .97 1.04 1.01 1.03 1.01 1.05 1.06
ATP 1.02 1.04 1.00 1.02 1.02 1.10 1.06
KLA/ATP 1.00 1.00 .98 1.07 1.03 1.07 1.04
Flnc
KLA  ATP  ATP+KLA
 NM_001081185 filamin C, gamma (actin binding protein 280) (Flnc), mRNA [NM_001081185] KLA .95 1.00 1.02 1.00 .95 .98 1.05
ATP 1.02 1.01 1.11 1.37 1.04 1.04 1.13
KLA/ATP .99 1.02 .93 1.00 .90 .99 1.03
Flt1
KLA  ATP  ATP+KLA
 NM_010228 FMS-like tyrosine kinase 1 (Flt1), mRNA [NM_010228] KLA 3.02 2.74 2.92 3.54 3.71 3.82 1.43
ATP .88 .85 1.07 .85 .94 1.31 1.16
KLA/ATP 2.60 2.99 3.08 2.13 2.23 2.00 2.59
Flt4
KLA  ATP  ATP+KLA
 NM_008029 FMS-like tyrosine kinase 4 (Flt4), mRNA [NM_008029] KLA 1.04 1.02 1.01 1.00 1.10 1.01 1.01
ATP 1.02 1.08 1.07 .99 .95 .97 1.02
KLA/ATP 1.08 1.06 1.00 1.02 .99 1.07 1.02
Fn1
KLA  ATP  ATP+KLA
 NM_010233 fibronectin 1 (Fn1), mRNA [NM_010233] KLA 1.23 1.30 1.38 1.12 1.16 1.00 .78
ATP 1.02 1.19 1.25 1.56 1.33 1.05 .95
KLA/ATP 1.36 1.51 1.34 1.70 1.20 1.06 .93
Fyn
KLA  ATP  ATP+KLA
 U70324 Fyn(T) (L-fyn(T)) mRNA, complete cds. [U70324] KLA 1.23 1.27 1.31 1.27 1.31 .87 .48
ATP .88 .71 .66 .75 .90 1.28 .51
KLA/ATP 1.12 1.01 .94 .84 1.25 1.51 .53
Grb2
KLA  ATP  ATP+KLA
 NM_008163 growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] KLA .92 .88 .90 1.27 1.43 1.22 1.00
ATP 1.02 .83 .51 .42 .92 .70 .57
KLA/ATP .84 .77 .61 .56 1.56 1.49 .52
Grb2
KLA  ATP  ATP+KLA
 U07617 Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] KLA .83 .80 .95 1.13 1.38 1.36 1.06
ATP .84 .74 .51 .41 .82 .74 .59
KLA/ATP .77 .70 .57 .54 1.49 1.39 .53
Grlf1
KLA  ATP  ATP+KLA
 NM_172739 glucocorticoid receptor DNA binding factor 1 (Grlf1), mRNA [NM_172739] KLA 1.65 1.31 1.14 1.07 .99 1.16 .94
ATP .85 .69 .90 .69 .86 1.87 .87
KLA/ATP 1.26 1.23 1.21 .76 1.23 1.99 1.66
Gsk3b
KLA  ATP  ATP+KLA
 NM_019827 glycogen synthase kinase 3 beta (Gsk3b), mRNA [NM_019827] KLA 1.06 1.03 1.11 1.01 1.26 1.28 1.26
ATP 1.18 1.27 1.15 2.07 2.37 2.32 1.67
KLA/ATP 1.15 1.21 .98 1.50 1.67 2.50 2.99
Hgf
KLA  ATP  ATP+KLA
 AK033274 15 days embryo male testis cDNA, RIKEN full-length enriched library, clone:8030481P22 product:inferred: hepatocyte growth factor [AK033274] KLA 1.34 1.22 .96 .93 .82 .93 .87
ATP 1.64 2.45 3.30 1.89 .97 1.12 .90
KLA/ATP 1.49 2.50 3.96 1.88 1.07 1.00 .83
Hgf
KLA  ATP  ATP+KLA
 NM_010427 hepatocyte growth factor (Hgf), mRNA [NM_010427] KLA 1.11 1.18 1.30 1.20 1.08 .96 1.14
ATP 1.02 1.14 1.32 1.62 1.17 1.26 1.47
KLA/ATP 1.18 1.24 1.33 1.84 1.19 1.09 1.31
Hras1
KLA  ATP  ATP+KLA
 NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Ibsp
KLA  ATP  ATP+KLA
 NM_008318 integrin binding sialoprotein (Ibsp), mRNA [NM_008318] KLA .99 1.02 1.05 .96 .98 .96 .97
ATP .98 .99 .99 .96 1.00 1.02 1.00
KLA/ATP 1.01 1.07 1.03 .93 .93 .95 .95
Igf1
KLA  ATP  ATP+KLA
 AK050118 adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730016P09 product:unclassifiable, full insert sequence. [AK050118] KLA .13 .14 .15 .16 .22 .34 .48
ATP 1.78 2.05 1.37 .72 .34 .41 .58
KLA/ATP .24 .45 .50 .24 .20 .26 .68
Igf1
KLA  ATP  ATP+KLA
 NM_010512 insulin-like growth factor 1 (Igf1), transcript variant 1, mRNA [NM_010512] KLA .84 .78 .76 .67 .54 .48 .59
ATP .97 .98 1.13 1.13 1.03 .88 .89
KLA/ATP .82 .81 .93 .86 .83 .65 .89
Igf1
KLA  ATP  ATP+KLA
 NM_184052 insulin-like growth factor 1 (Igf1), transcript variant 2, mRNA [NM_184052] KLA .77 .82 .76 .65 .60 .52 .69
ATP 1.01 1.07 .98 1.06 1.03 .78 .94
KLA/ATP .89 .86 .77 .80 .75 .65 .89
Igf1r
KLA  ATP  ATP+KLA
 NM_010513 insulin-like growth factor I receptor (Igf1r), mRNA [NM_010513] KLA 1.32 1.32 1.08 .91 .55 .48 .45
ATP 1.03 1.06 1.06 1.29 1.31 1.45 .47
KLA/ATP 1.30 1.37 1.11 1.00 .93 1.02 .45
Ilk
KLA  ATP  ATP+KLA
 NM_010562 integrin linked kinase (Ilk), mRNA [NM_010562] KLA .84 .85 .92 .81 .97 .96 .67
ATP 1.03 1.11 .85 1.07 .82 .66 .91
KLA/ATP .93 .90 .58 .94 .63 .63 .80
Itga1
KLA  ATP  ATP+KLA
 NM_001033228 integrin alpha 1 (Itga1), mRNA [NM_001033228] KLA 1.08 1.09 1.13 1.05 1.04 .99 1.01
ATP 1.02 .97 1.03 1.03 1.09 1.43 3.50
KLA/ATP 1.06 1.04 1.07 1.00 1.06 1.12 1.33
Itga10
KLA  ATP  ATP+KLA
 NM_001081053 integrin, alpha 10 (Itga10), mRNA [NM_001081053] KLA .98 1.00 1.00 1.04 1.04 .96 1.00
ATP 1.05 1.00 .97 .98 .95 .96 .97
KLA/ATP 1.04 .98 .92 .96 .95 .97 1.00
Itga11
KLA  ATP  ATP+KLA
 NM_176922 integrin, alpha 11 (Itga11), mRNA [NM_176922] KLA .95 .92 .90 .97 .93 .93 .96
ATP .97 .92 .98 .95 .90 .94 .95
KLA/ATP .86 .94 1.01 .93 .97 .94 .88
Itga2
KLA  ATP  ATP+KLA
 NM_008396 integrin alpha 2 (Itga2), mRNA [NM_008396] KLA 1.03 1.00 .98 1.01 .97 .96 1.00
ATP 1.05 .99 .93 1.02 1.04 1.03 .97
KLA/ATP .98 1.06 1.03 1.00 1.00 1.01 1.01
Itga2b
KLA  ATP  ATP+KLA
 NM_010575 integrin alpha 2b (Itga2b), mRNA [NM_010575] KLA 1.01 1.00 .98 1.04 1.01 1.04 1.18
ATP 1.01 .98 .95 1.02 .96 1.13 1.08
KLA/ATP 1.04 1.02 1.02 .95 1.05 1.53 1.23
Itga3
KLA  ATP  ATP+KLA
 NM_013565 integrin alpha 3 (Itga3), mRNA [NM_013565] KLA 1.06 1.09 1.10 1.17 1.19 1.29 1.41
ATP .99 .99 1.05 1.12 1.20 1.25 1.33
KLA/ATP 1.08 1.14 1.15 1.27 1.28 1.20 1.39
Itga4
KLA  ATP  ATP+KLA
 NM_010576 integrin alpha 4 (Itga4), mRNA [NM_010576] KLA 4.65 4.83 4.47 3.76 2.93 1.65 1.01
ATP 1.10 1.12 1.17 1.08 .86 .75 .36
KLA/ATP 4.82 5.02 4.43 3.69 2.11 1.13 .79
Itga5
KLA  ATP  ATP+KLA
 NM_010577 integrin alpha 5 (fibronectin receptor alpha) (Itga5), mRNA [NM_010577] KLA 2.63 3.04 2.81 2.47 4.61 5.45 4.90
ATP 1.13 1.62 .74 2.21 1.31 1.93 2.84
KLA/ATP 3.55 3.84 1.15 3.03 1.11 2.81 10.42
Itga6
KLA  ATP  ATP+KLA
 BC024571 integrin alpha 6, mRNA (cDNA clone IMAGE:5036677). [BC024571] KLA .44 .44 .37 .28 .25 .29 .34
ATP .96 1.01 .90 .58 .35 .11 .22
KLA/ATP .44 .41 .34 .23 .15 .09 .08
Itga6
KLA  ATP  ATP+KLA
 NM_008397 integrin alpha 6 (Itga6), mRNA [NM_008397] KLA .57 .58 .51 .45 .43 .44 .47
ATP 1.05 1.12 .86 .90 .57 .27 .36
KLA/ATP .64 .67 .50 .57 .39 .29 .26
Itga7
KLA  ATP  ATP+KLA
 L23423 gb|Mouse (BALB/c) alpha-7 integrin mRNA, complete cds. [L23423] KLA .96 1.03 1.00 1.07 1.02 1.07 1.14
ATP 1.00 1.00 1.04 1.88 2.09 1.34 1.16
KLA/ATP 1.04 .97 1.07 1.79 1.68 1.39 1.11
Itga7
KLA  ATP  ATP+KLA
 NM_008398 integrin alpha 7 (Itga7), mRNA [NM_008398] KLA .98 .95 .98 1.01 1.04 1.03 .98
ATP 1.00 1.02 1.06 1.75 1.92 1.20 1.02
KLA/ATP 1.03 1.07 1.06 1.48 1.58 1.23 1.05
Itga8
KLA  ATP  ATP+KLA
 NM_001001309 integrin alpha 8 (Itga8), mRNA [NM_001001309] KLA .80 .81 .79 .75 .63 .61 .44
ATP .98 1.04 1.06 .94 .79 .61 .50
KLA/ATP .79 .81 .81 .71 .70 .65 .48
Itgav
KLA  ATP  ATP+KLA
 AK052514 13 days embryo lung cDNA, RIKEN full-length enriched library, clone:D430040G12 product:hypothetical protein, full insert sequence. [AK052514] KLA 1.04 .93 1.05 1.02 1.01 .93 1.03
ATP 1.05 1.04 1.13 1.12 1.12 .91 1.02
KLA/ATP 1.08 .97 1.02 .95 1.01 .96 1.05
Itgav
KLA  ATP  ATP+KLA
 AK171739 activated spleen cDNA, RIKEN full-length enriched library, clone:F830008B15 product:unclassifiable, full insert sequence. [AK171739] KLA 1.04 .97 1.06 .95 1.15 .89 1.11
ATP 1.41 1.54 1.64 2.24 2.74 1.24 1.18
KLA/ATP 1.09 1.07 1.03 1.01 1.72 1.24 1.10
Itgav
KLA  ATP  ATP+KLA
 NM_008402 integrin alpha V (Itgav), mRNA [NM_008402] KLA 4.00 3.99 3.28 2.24 1.57 .95 1.13
ATP 1.14 1.22 1.13 1.39 2.22 2.47 1.70
KLA/ATP 4.59 4.61 2.48 2.44 1.60 1.88 2.56
Itgb1
KLA  ATP  ATP+KLA
 NM_010578 integrin beta 1 (fibronectin receptor beta) (Itgb1), mRNA [NM_010578] KLA 1.05 1.09 1.13 .92 1.01 .93 .88
ATP 1.14 1.30 .92 1.07 1.04 .83 .70
KLA/ATP 1.26 1.30 .87 1.02 .66 .65 .62
Itgb1
KLA  ATP  ATP+KLA
 U37029 integrin beta1D mRNA, partial cds. [U37029] KLA .93 .95 .96 1.01 .97 1.01 .98
ATP 1.05 .99 .99 1.03 1.03 .97 .94
KLA/ATP .99 .98 1.04 .97 1.02 1.01 .99
Itgb3
KLA  ATP  ATP+KLA
 AF026509 integrin beta3 subunit mRNA, complete cds. [AF026509] KLA 2.38 2.64 2.65 3.15 4.02 4.46 2.83
ATP 1.21 1.17 1.25 1.62 2.33 3.09 4.78
KLA/ATP 2.48 2.63 3.39 3.72 4.30 4.71 6.79
Itgb3
KLA  ATP  ATP+KLA
 NM_016780 integrin beta 3 (Itgb3), mRNA [NM_016780] KLA .50 .51 .52 .41 .31 .25 .15
ATP .94 .88 1.17 .89 .99 1.36 .91
KLA/ATP .51 .54 .67 .52 .61 .74 .48
Itgb4
KLA  ATP  ATP+KLA
 AK048888 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230078O20 product:integrin beta 4, full insert sequence. [AK048888] KLA .98 .92 .98 1.08 .97 1.02 1.02
ATP .99 .99 .91 1.03 1.02 1.00 1.05
KLA/ATP .99 1.03 .99 .98 .94 .98 1.01
Itgb4
KLA  ATP  ATP+KLA
 NM_001005608 integrin beta 4 (Itgb4), transcript variant 1, mRNA [NM_001005608] KLA 1.09 1.11 1.12 1.08 .98 .86 .85
ATP .90 .89 .90 .95 .87 .87 .84
KLA/ATP 1.06 1.08 1.10 1.18 1.07 .90 .76
Itgb5
KLA  ATP  ATP+KLA
 NM_010580 integrin beta 5 (Itgb5), mRNA [NM_010580] KLA .72 .68 .67 .66 .54 .43 .36
ATP 1.09 .94 .78 .57 .63 .56 .62
KLA/ATP .78 .64 .67 .51 .64 .67 .38
Itgb6
KLA  ATP  ATP+KLA
 NM_021359 integrin beta 6 (Itgb6), mRNA [NM_021359] KLA .97 1.02 1.04 1.06 1.06 1.04 1.01
ATP .99 1.00 1.01 .96 1.04 1.00 1.00
KLA/ATP .99 1.03 1.08 1.02 1.02 1.03 1.01
Itgb7
KLA  ATP  ATP+KLA
 NM_013566 integrin beta 7 (Itgb7), mRNA [NM_013566] KLA .91 .88 .93 1.19 .93 .76 .79
ATP 1.00 .96 1.30 1.44 2.84 3.07 7.90
KLA/ATP .96 1.05 1.35 1.20 2.70 3.53 8.17
Itgb8
KLA  ATP  ATP+KLA
 AK029281 0 day neonate head cDNA, RIKEN full-length enriched library, clone:4832412O06 product:SIMILAR TO INTEGRIN, BETA 8 homolog [Homo sapiens], full insert sequence. [AK029281] KLA 4.66 5.00 3.59 2.70 1.76 1.34 1.32
ATP 1.01 .98 1.09 1.16 2.15 5.24 1.17
KLA/ATP 5.59 6.39 4.38 1.99 1.84 2.55 2.11
Itgb8
KLA  ATP  ATP+KLA
 AK034644 12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library, clone:9430018C17 product:integrin beta 8, full insert sequence. [AK034644] KLA 1.18 1.02 1.04 1.03 1.05 .94 .93
ATP .96 .97 .97 .96 .90 1.04 .99
KLA/ATP 1.06 1.06 1.15 .92 .99 1.00 1.09
Itgb8
KLA  ATP  ATP+KLA
 AK140969 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130086L01 product:hypothetical protein, full insert sequence [AK140969] KLA 3.63 3.76 4.16 3.31 2.72 1.58 1.40
ATP .98 1.01 1.31 1.14 1.28 6.11 1.65
KLA/ATP 3.84 4.18 3.75 2.83 1.92 3.44 4.81
Jun
KLA  ATP  ATP+KLA
 NM_010591 Jun oncogene (Jun), mRNA [NM_010591] KLA 1.08 .96 1.09 1.09 .75 .88 .81
ATP 1.26 1.48 4.45 8.73 4.02 1.16 1.99
KLA/ATP 1.12 1.38 3.52 5.17 3.32 .49 1.42
Kdr
KLA  ATP  ATP+KLA
 AK054510 2 days pregnant adult female ovary cDNA, RIKEN full-length enriched library, clone:E330034B14 product:kinase insert domain protein receptor, full insert sequence. [AK054510] KLA 1.00 1.00 .98 1.03 1.02 1.00 .99
ATP .99 1.00 1.00 1.02 1.00 1.00 1.00
KLA/ATP 1.01 1.02 1.03 1.02 .98 1.00 1.01
Kdr
KLA  ATP  ATP+KLA
 NM_010612 kinase insert domain protein receptor (Kdr), mRNA [NM_010612] KLA 7.30 7.28 6.48 6.79 5.97 6.18 2.71
ATP 1.00 .84 1.06 1.14 3.62 3.10 7.15
KLA/ATP 6.62 7.17 7.12 6.48 14.11 12.63 11.01
Lama1
KLA  ATP  ATP+KLA
 NM_008480 laminin, alpha 1 (Lama1), mRNA [NM_008480] KLA .99 1.04 .97 .96 1.01 .99 1.05
ATP 1.01 .99 .98 1.05 .99 1.09 .99
KLA/ATP 1.00 .97 .86 1.04 1.05 .99 1.00
Lama2
KLA  ATP  ATP+KLA
 AK046114 adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230342M05 product:laminin, alpha 2, full insert sequence. [AK046114] KLA 1.06 1.00 .95 1.10 1.04 .99 .96
ATP .98 1.09 1.00 .97 .96 1.12 1.01
KLA/ATP .94 1.04 1.05 1.00 .99 1.00 .98
Lama2
KLA  ATP  ATP+KLA
 NM_008481 laminin, alpha 2 (Lama2), mRNA [NM_008481] KLA .96 .99 .96 1.02 .95 1.00 .97
ATP 1.05 1.00 1.01 .94 1.01 1.04 .96
KLA/ATP .99 1.04 1.06 1.10 .98 .95 .97
Lama2
KLA  ATP  ATP+KLA
 U12147 laminin-2 alpha2 chain mRNA, complete cds. [U12147] KLA .96 1.00 .99 1.00 .98 1.02 1.03
ATP 1.01 .99 1.02 1.04 1.01 .99 1.02
KLA/ATP 1.00 1.01 1.00 1.01 .99 1.04 1.00
Lama3
KLA  ATP  ATP+KLA
 XM_140451 gb|PREDICTED: Mus musculus laminin, alpha 3, transcript variant 1 (Lama3), mRNA [XM_140451] KLA .76 .75 .73 .75 .71 .74 .67
ATP 1.04 1.12 1.05 1.20 .88 .73 .78
KLA/ATP .77 .81 .78 .82 .78 .71 .70
Lama4
KLA  ATP  ATP+KLA
 NM_010681 laminin, alpha 4 (Lama4), mRNA [NM_010681] KLA .99 .99 1.01 1.02 .98 .97 .96
ATP 1.00 1.08 1.05 1.05 1.03 1.04 .96
KLA/ATP 1.00 1.03 .93 1.00 .94 .90 .95
Lama5
KLA  ATP  ATP+KLA
 NM_001081171 laminin, alpha 5 (Lama5), mRNA [NM_001081171] KLA 1.11 1.07 1.09 1.00 .96 1.00 1.01
ATP 1.01 .99 1.03 1.01 1.00 .99 .99
KLA/ATP 1.12 1.08 1.05 1.04 .99 1.09 1.04
Lamb1-1
KLA  ATP  ATP+KLA
 NM_008482 laminin B1 subunit 1 (Lamb1-1), mRNA [NM_008482] KLA .93 .99 1.10 1.01 .95 1.00 .86
ATP .99 1.13 1.06 .99 1.07 .99 .97
KLA/ATP 1.00 1.06 .98 .95 .93 .89 1.04
Lamb2
KLA  ATP  ATP+KLA
 NM_008483 laminin, beta 2 (Lamb2), mRNA [NM_008483] KLA .93 .90 .95 .81 .79 .58 .37
ATP 1.01 1.09 .95 .99 .80 .81 .38
KLA/ATP .96 .87 1.00 .91 .72 .60 .38
Lamb3
KLA  ATP  ATP+KLA
 NM_008484 laminin, beta 3 (Lamb3), mRNA [NM_008484] KLA 1.00 .97 1.02 .98 1.00 1.04 .93
ATP 1.01 1.01 .91 .97 .89 1.04 1.03
KLA/ATP 1.00 .95 .97 1.00 .95 .87 1.02
Lamc1
KLA  ATP  ATP+KLA
 J03484 gb|Mouse laminin B2 chain mRNA, complete cds [J03484] KLA 1.14 1.01 1.04 .87 .82 .63 .75
ATP .99 1.09 1.07 1.14 1.36 2.38 .66
KLA/ATP 1.04 1.10 .95 1.12 1.30 1.70 .68
Lamc2
KLA  ATP  ATP+KLA
 AF106279 laminin gamma2 chain mRNA, partial cds. [AF106279] KLA 1.03 1.04 1.03 1.09 .97 .97 .98
ATP 1.04 1.04 1.16 1.48 1.46 1.29 1.26
KLA/ATP 1.04 1.00 1.03 1.06 .95 .99 1.08
Lamc2
KLA  ATP  ATP+KLA
 NM_008485 laminin, gamma 2 (Lamc2), mRNA [NM_008485] KLA 1.16 1.22 1.23 1.07 1.04 1.12 1.04
ATP 1.01 1.10 2.81 4.58 4.35 3.34 2.36
KLA/ATP 1.31 1.29 1.41 1.40 1.28 1.25 1.49
Lamc3
KLA  ATP  ATP+KLA
 AF083372 laminin 12 gamma 3 chain mRNA, complete cds. [AF083372] KLA .96 .94 .99 .96 .94 1.02 .88
ATP 1.06 1.00 .95 .98 .98 .99 1.02
KLA/ATP .90 .98 1.03 .95 .88 .97 .96
Lamc3
KLA  ATP  ATP+KLA
 NM_011836 laminin gamma 3 (Lamc3), mRNA [NM_011836] KLA 1.00 1.00 1.04 1.04 1.03 1.01 .97
ATP .99 1.06 1.00 .91 .98 .96 1.01
KLA/ATP .98 1.04 1.01 1.02 .96 .95 .98
Map2k1
KLA  ATP  ATP+KLA
 NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk10
KLA  ATP  ATP+KLA
 AK076990 adult male testis cDNA, RIKEN full-length enriched library, clone:4930597C01 product:mitogen activated protein kinase 10, full insert sequence. [AK076990] KLA 1.03 1.05 .98 1.04 .94 .95 1.02
ATP 1.00 .99 1.06 .97 1.01 .96 .99
KLA/ATP 1.07 1.01 .95 1.05 .82 .95 .87
Mapk10
KLA  ATP  ATP+KLA
 NM_009158 mitogen-activated protein kinase 10 (Mapk10), transcript variant 1, mRNA [NM_009158] KLA .95 1.00 .97 1.01 .99 1.01 .95
ATP 1.01 1.02 .98 1.01 1.04 1.01 .99
KLA/ATP 1.05 .99 1.01 .98 .92 .97 .98
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Mapk8
KLA  ATP  ATP+KLA
 AK162915 adult male spinal cord cDNA, RIKEN full-length enriched library, clone:A330031O19 product:mitogen activated protein kinase 8, full insert sequence [AK162915] KLA .94 .86 .80 .83 .77 .85 .83
ATP 1.08 1.12 .94 .80 .83 .71 .75
KLA/ATP .83 .81 .80 .74 .74 .75 .67
Mapk8
KLA  ATP  ATP+KLA
 AK163829 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130070A06 product:mitogen activated protein kinase 8, full insert sequence [AK163829] KLA .65 .61 .66 .70 .90 1.02 1.03
ATP .99 .94 1.68 1.44 1.75 1.84 1.10
KLA/ATP .63 .67 1.11 1.00 2.01 1.68 1.15
Mapk8
KLA  ATP  ATP+KLA
 NM_016700 mitogen-activated protein kinase 8 (Mapk8), mRNA [NM_016700] KLA .96 1.00 .94 .96 .94 .99 1.04
ATP 1.01 1.05 1.01 .99 1.03 .98 1.02
KLA/ATP .96 .97 .96 .97 .93 .94 .96
Mapk9
KLA  ATP  ATP+KLA
 NM_016961 mitogen-activated protein kinase 9 (Mapk9), transcript variant 2, mRNA [NM_016961] KLA 1.28 1.37 1.59 1.60 1.61 1.43 1.38
ATP 1.03 .99 .74 .71 .79 1.20 1.01
KLA/ATP 1.53 1.30 1.07 .99 .83 1.10 1.40
Mapk9
KLA  ATP  ATP+KLA
 NM_207692 mitogen-activated protein kinase 9 (Mapk9), transcript variant 1, mRNA [NM_207692] KLA 1.39 1.53 1.69 1.69 1.55 1.44 1.51
ATP .95 .92 .75 .85 .70 1.46 1.17
KLA/ATP 1.37 1.35 .99 1.18 .91 1.22 1.62
Met
KLA  ATP  ATP+KLA
 NM_008591 met proto-oncogene (Met), mRNA [NM_008591] KLA 3.56 3.71 3.68 3.79 4.24 5.89 6.95
ATP .98 .96 1.16 1.21 3.32 12.98 6.60
KLA/ATP 3.75 3.80 3.58 3.28 3.69 4.27 14.22
Mm.13157
2
KLA  ATP  ATP+KLA
 134949023 Unknown KLA 1.04 1.01 .96 .95 .95 1.00 .99
ATP .98 1.02 .99 1.07 .97 .96 1.00
KLA/ATP .96 .88 .91 1.00 1.02 .98 1.05
Mm.19309
9
KLA  ATP  ATP+KLA
 46849811 Unknown KLA 1.32 1.36 1.42 1.17 1.06 .90 .58
ATP .98 1.12 1.41 1.81 1.44 1.14 .89
KLA/ATP 1.39 1.55 1.57 2.02 1.43 1.12 .74
Mm.21312
8
KLA  ATP  ATP+KLA
 141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.24185
7
KLA  ATP  ATP+KLA
 142347489 Unknown KLA 1.18 1.09 1.27 1.24 1.14 1.18 1.15
ATP 1.10 1.02 1.13 1.16 1.04 1.03 1.11
KLA/ATP 1.17 1.19 1.29 1.21 1.10 1.02 1.19
Mm.25381
9
KLA  ATP  ATP+KLA
 118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.25806
5
KLA  ATP  ATP+KLA
 148747407 Unknown KLA 1.05 1.02 1.03 1.00 .99 1.05 .94
ATP .98 .98 1.03 1.02 .99 1.06 1.03
KLA/ATP 1.01 1.02 1.03 1.01 .96 .98 1.01
Mm.26132
9
KLA  ATP  ATP+KLA
 71037402 Unknown KLA 1.53 1.44 1.59 1.66 1.72 1.88 1.09
ATP 1.08 .98 1.38 1.35 1.28 1.25 1.07
KLA/ATP 1.49 1.53 1.97 1.61 1.54 1.25 1.08
Mm.27304
9
KLA  ATP  ATP+KLA
 119672895 Unknown KLA .23 .22 .22 .22 .30 .51 .16
ATP 1.08 1.05 .88 .78 .47 .09 .20
KLA/ATP .28 .22 .21 .24 .26 .22 .12
Mm.27574
2
KLA  ATP  ATP+KLA
 112983655 Unknown KLA 1.35 1.16 .94 .85 .45 .33 .31
ATP .90 .86 1.17 1.09 1.18 1.21 .38
KLA/ATP 1.12 1.22 1.19 .91 .90 .83 .33
Mm.27604
2
KLA  ATP  ATP+KLA
 18702319 Unknown KLA .81 .72 .70 .70 .54 .54 .67
ATP .90 .95 1.17 1.15 1.35 1.32 1.13
KLA/ATP .70 .78 .89 .83 1.09 1.13 .97
Mm.33565
9
KLA  ATP  ATP+KLA
 160333365 Unknown KLA 5.54 4.69 3.93 3.03 2.00 1.91 1.69
ATP .98 .81 1.01 .78 .68 1.71 1.10
KLA/ATP 5.05 4.44 5.07 2.38 1.34 1.88 2.00
Mm.42523
6
KLA  ATP  ATP+KLA
 117320553 Unknown KLA .98 .98 1.03 1.00 .99 1.02 1.02
ATP 1.01 .99 1.03 1.02 1.05 .94 .96
KLA/ATP 1.08 1.04 1.06 1.01 1.00 1.01 1.05
Mm.4387
KLA  ATP  ATP+KLA
 133892666 Unknown KLA .85 .87 .85 .89 .77 .91 1.18
ATP 1.01 1.01 .87 1.07 .75 .86 .93
KLA/ATP .88 .86 .77 .81 .72 .91 .84
Mm.45157
8
KLA  ATP  ATP+KLA
 124486802 Unknown KLA .91 1.00 .99 .96 1.05 .99 1.02
ATP .96 1.06 1.02 .95 1.02 1.02 .97
KLA/ATP 1.06 1.00 1.04 1.01 .97 .94 1.05
Mm.45825
9
KLA  ATP  ATP+KLA
 116292181 Unknown KLA .84 .86 .91 .85 .98 .98 1.00
ATP 1.05 1.06 .94 .95 1.00 .89 .89
KLA/ATP .92 .84 .87 .93 .91 .92 .82
Mm.46042
5
KLA  ATP  ATP+KLA
 145699103 Unknown KLA .97 1.06 1.00 1.00 1.04 1.00 1.06
ATP .98 1.03 .96 .96 1.00 1.05 .96
KLA/ATP .99 .95 1.04 .97 1.01 .98 .93
Mm.46514
KLA  ATP  ATP+KLA
 114326498 Unknown KLA 1.06 .98 1.04 .98 1.00 .99 .99
ATP 1.03 .95 1.00 .93 1.00 1.00 .98
KLA/ATP 1.06 .99 .94 .95 .90 .91 1.02
Mm.4987
KLA  ATP  ATP+KLA
 160358832 Unknown KLA 1.04 1.02 1.05 1.00 1.06 1.02 1.00
ATP 1.11 1.00 1.08 1.01 1.05 1.09 1.04
KLA/ATP 1.08 1.05 .94 1.04 1.06 1.11 .99
Myl2
KLA  ATP  ATP+KLA
 NM_010861 myosin, light polypeptide 2, regulatory, cardiac, slow (Myl2), mRNA [NM_010861] KLA .88 .93 .94 .95 .94 .77 .60
ATP .96 1.04 1.14 1.06 1.00 .93 .66
KLA/ATP .91 .85 1.07 1.03 .88 .79 .67
Myl7
KLA  ATP  ATP+KLA
 NM_022879 myosin, light polypeptide 7, regulatory (Myl7), mRNA [NM_022879] KLA .95 1.01 1.02 .97 1.00 1.04 1.01
ATP 1.01 1.02 .96 .98 1.00 .98 1.01
KLA/ATP .98 1.06 1.03 .97 .85 1.01 1.00
Mylc2b
KLA  ATP  ATP+KLA
 NM_023402 myosin light chain, regulatory B (Mylc2b), mRNA [NM_023402] KLA .88 .84 .82 .86 .84 1.03 1.08
ATP .97 1.02 1.12 1.24 .96 .83 1.23
KLA/ATP .84 .83 .87 .97 .86 .91 1.34
Mylc2pl
KLA  ATP  ATP+KLA
 NM_021611 myosin light chain 2, precursor lymphocyte-specific (Mylc2pl), transcript variant 1, mRNA [NM_021611] KLA .99 .97 .93 1.05 1.00 1.03 1.00
ATP .99 1.01 1.03 1.03 .98 .97 1.06
KLA/ATP .97 1.03 .93 1.01 .97 1.05 1.05
Mylk
KLA  ATP  ATP+KLA
 AK044527 adult retina cDNA, RIKEN full-length enriched library, clone:A930019C19 product:MYOSIN LIGHT CHAIN KINASE (FRAGMENT) homolog [Mus musculus], full insert sequence. [AK044527] KLA 1.10 .99 .93 1.01 1.00 1.07 1.01
ATP 1.02 .97 .92 .99 1.02 .97 1.06
KLA/ATP 1.01 1.03 1.05 .97 .91 1.00 .96
Mylk
KLA  ATP  ATP+KLA
 NM_139300 myosin, light polypeptide kinase (Mylk), mRNA [NM_139300] KLA 1.05 1.15 1.22 1.24 1.33 1.21 .50
ATP 1.05 1.08 .96 .91 .79 .71 .40
KLA/ATP 1.14 1.18 1.15 1.04 .90 .79 .48
Mylk2
KLA  ATP  ATP+KLA
 NM_001081044 myosin, light polypeptide kinase 2, skeletal muscle (Mylk2), mRNA [NM_001081044] KLA 1.17 1.21 1.11 1.25 1.17 1.10 1.06
ATP .94 1.05 1.06 1.10 1.33 1.33 1.27
KLA/ATP 1.15 1.25 1.14 1.21 1.32 1.29 1.45
Mylk3
KLA  ATP  ATP+KLA
 AK052858 16 days neonate heart cDNA, RIKEN full-length enriched library, clone:D830007F02 product:Weakly similar to myosin light chain kinase, full insert sequence. [AK052858] KLA 1.06 1.02 .95 .98 1.01 1.04 1.02
ATP 1.02 1.06 1.00 1.01 .97 1.01 .98
KLA/ATP 1.08 1.00 .94 1.13 1.07 1.08 1.05
Mylpf
KLA  ATP  ATP+KLA
 NM_016754 myosin light chain, phosphorylatable, fast skeletal muscle (Mylpf), mRNA [NM_016754] KLA 1.07 1.12 1.08 1.20 1.17 1.27 1.34
ATP 1.00 .90 .98 1.08 .98 1.22 1.09
KLA/ATP 1.00 1.15 1.14 1.18 1.18 1.04 1.19
Pak1
KLA  ATP  ATP+KLA
 NM_011035 p21 (CDKN1A)-activated kinase 1 (Pak1), mRNA [NM_011035] KLA .72 .77 .79 .71 .67 .73 .95
ATP 1.10 1.07 .99 1.15 1.27 .62 .51
KLA/ATP .85 .83 .73 .76 .76 .55 .33
Pak2
KLA  ATP  ATP+KLA
 NM_177326 p21 (CDKN1A)-activated kinase 2 (Pak2), mRNA [NM_177326] KLA 1.23 1.24 1.26 1.17 1.19 1.09 1.13
ATP 1.04 1.01 .65 .58 .82 1.18 1.45
KLA/ATP 1.26 1.26 .78 .72 .71 .95 1.44
Pak3
KLA  ATP  ATP+KLA
 NM_008778 p21 (CDKN1A)-activated kinase 3 (Pak3), mRNA [NM_008778] KLA 1.06 1.02 1.03 1.00 1.06 1.01 1.01
ATP 1.05 1.01 1.03 .97 .98 1.08 1.07
KLA/ATP 1.00 .99 .99 1.03 1.00 1.01 1.08
Pak4
KLA  ATP  ATP+KLA
 NM_027470 p21 (CDKN1A)-activated kinase 4 (Pak4), mRNA [NM_027470] KLA 1.41 1.51 1.62 1.57 1.88 1.26 1.06
ATP 1.13 1.15 1.04 1.21 1.73 1.45 1.03
KLA/ATP 1.58 1.60 1.31 1.65 1.84 1.64 1.40
Pak6
KLA  ATP  ATP+KLA
 AK028788 10 days neonate skin cDNA, RIKEN full-length enriched library, clone:4732456M09 product:p21 (CDKN1A)-activated kinase 6, full insert sequence. [AK028788] KLA 1.38 1.33 1.40 1.45 1.42 1.49 1.20
ATP .95 .93 1.15 1.21 1.21 1.32 1.10
KLA/ATP 1.33 1.38 1.55 1.44 1.57 1.45 1.36
Pak7
KLA  ATP  ATP+KLA
 AK077967 13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030481C12 product:hypothetical protein, full insert sequence. [AK077967] KLA 1.00 1.01 1.07 1.02 .99 1.01 1.05
ATP .93 .95 1.03 1.01 1.02 .92 1.00
KLA/ATP 1.04 1.01 .99 1.04 .99 1.06 1.02
Parva
KLA  ATP  ATP+KLA
 NM_020606 parvin, alpha (Parva), mRNA [NM_020606] KLA 1.00 .95 1.02 1.03 1.03 1.10 .92
ATP .97 1.03 .92 1.00 .95 1.03 1.04
KLA/ATP .96 .98 1.00 1.01 .98 .94 1.00
Parvb
KLA  ATP  ATP+KLA
 NM_133167 parvin, beta (Parvb), mRNA [NM_133167] KLA .92 .95 .85 .80 .72 .72 .78
ATP 1.01 1.18 .97 1.25 1.15 1.00 1.23
KLA/ATP .96 .99 .76 .98 .75 .78 .79
Parvg
KLA  ATP  ATP+KLA
 NM_022321 parvin, gamma (Parvg), mRNA [NM_022321] KLA .91 .88 .89 .74 .74 .61 .64
ATP 1.18 1.26 1.03 1.45 1.33 .67 1.20
KLA/ATP 1.04 1.08 .80 1.00 .79 .66 .81
Pdgfa
KLA  ATP  ATP+KLA
 NM_008808 platelet derived growth factor, alpha (Pdgfa), mRNA [NM_008808] KLA .63 .56 .42 .34 .31 .33 .52
ATP .89 .80 .69 1.23 5.97 3.99 2.73
KLA/ATP .64 .53 .43 .77 3.48 3.78 2.37
Pdgfb
KLA  ATP  ATP+KLA
 NM_011057 platelet derived growth factor, B polypeptide (Pdgfb), mRNA [NM_011057] KLA .45 .43 .38 .46 .69 .48 .58
ATP .94 .95 .66 .74 .67 .77 1.06
KLA/ATP .43 .43 .37 .39 .52 .55 1.64
Pdgfc
KLA  ATP  ATP+KLA
 AK081347 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130008P20 product:platelet-derived growth factor, C polypeptide, full insert sequence. [AK081347] KLA .93 1.07 1.00 1.03 .93 .95 .98
ATP 1.05 1.04 .94 1.02 1.04 1.00 1.05
KLA/ATP 1.06 1.02 .99 .96 .99 1.05 1.01
Pdgfc
KLA  ATP  ATP+KLA
 NM_019971 platelet-derived growth factor, C polypeptide (Pdgfc), mRNA [NM_019971] KLA 1.56 1.52 1.84 2.08 1.83 1.33 .79
ATP .98 .91 .86 .91 .78 1.43 3.28
KLA/ATP 1.45 1.50 1.25 1.73 1.99 1.56 1.12
Pdgfd
KLA  ATP  ATP+KLA
 AK141551 adult male hippocampus cDNA, RIKEN full-length enriched library, clone:C630020I23 product:platelet-derived growth factor, D polypeptide, full insert sequence [AK141551] KLA 1.07 1.01 1.06 .98 .94 1.00 1.00
ATP .98 .99 1.10 1.00 .96 1.00 .94
KLA/ATP 1.00 1.03 1.05 1.02 .94 .97 1.03
Pdgfd
KLA  ATP  ATP+KLA
 NM_027924 platelet-derived growth factor, D polypeptide (Pdgfd), mRNA [NM_027924] KLA .99 .93 .95 .97 1.00 .99 .95
ATP 1.01 .99 1.00 .93 1.05 1.04 1.06
KLA/ATP .91 .91 .96 .92 .92 .99 1.05
Pdgfra
KLA  ATP  ATP+KLA
 NM_011058 platelet derived growth factor receptor, alpha polypeptide (Pdgfra), transcript variant 1, mRNA [NM_011058] KLA 1.02 1.05 1.02 1.01 1.03 1.03 1.01
ATP 1.01 1.02 1.03 1.04 1.00 1.01 1.01
KLA/ATP 1.01 1.01 .99 1.03 1.02 1.03 1.01
Pdgfrb
KLA  ATP  ATP+KLA
 NM_008809 platelet derived growth factor receptor, beta polypeptide (Pdgfrb), mRNA [NM_008809] KLA 4.85 5.49 4.56 3.94 3.71 2.05 1.51
ATP .99 1.00 1.11 1.27 1.02 1.83 1.23
KLA/ATP 5.09 5.86 4.30 2.51 1.74 1.84 3.23
Pdpk1
KLA  ATP  ATP+KLA
 NM_011062 3-phosphoinositide dependent protein kinase-1 (Pdpk1), transcript variant 1, mRNA [NM_011062] KLA .90 .90 .84 1.00 1.32 1.19 1.15
ATP 1.05 1.09 1.04 1.14 1.31 .97 1.17
KLA/ATP .90 .89 .91 1.02 1.27 .96 1.42
Pgf
KLA  ATP  ATP+KLA
 NM_008827 placental growth factor (Pgf), mRNA [NM_008827] KLA 1.59 1.43 1.58 1.66 1.51 1.67 1.19
ATP .94 1.05 1.49 3.36 5.65 4.56 3.89
KLA/ATP 1.64 1.61 1.95 2.17 3.19 4.33 4.95
Pik3ca
KLA  ATP  ATP+KLA
 ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
 NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
 NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
 NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
 U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
 NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
 NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
 NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
 NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
 NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Pip5k1c
KLA  ATP  ATP+KLA
 BC094665 phosphatidylinositol-4-phosphate 5-kinase, type 1 gamma, mRNA (cDNA clone MGC:102155 IMAGE:30356181), complete cds [BC094665] KLA .82 .90 .90 .70 .96 .86 1.21
ATP 1.19 1.45 .92 1.64 1.17 .83 1.33
KLA/ATP .97 1.21 .66 1.20 .91 .92 1.69
Pip5k1c
KLA  ATP  ATP+KLA
 NM_008844 phosphatidylinositol-4-phosphate 5-kinase, type 1 gamma (Pip5k1c), mRNA [NM_008844] KLA 1.40 1.36 1.38 1.39 1.30 1.30 1.27
ATP 1.01 1.16 1.12 1.46 1.38 1.35 1.21
KLA/ATP 1.39 1.44 1.44 1.64 1.41 1.45 1.53
Ppp1ca
KLA  ATP  ATP+KLA
 NM_031868 protein phosphatase 1, catalytic subunit, alpha isoform (Ppp1ca), mRNA [NM_031868] KLA .89 .93 .93 .86 .95 1.07 1.20
ATP 1.04 1.07 .93 1.02 1.01 .89 1.10
KLA/ATP .98 .93 .74 .91 .84 1.01 1.34
Ppp1cb
KLA  ATP  ATP+KLA
 NM_172707 protein phosphatase 1, catalytic subunit, beta isoform (Ppp1cb), mRNA [NM_172707] KLA 1.12 1.08 1.05 1.02 .89 .84 .94
ATP .89 .87 .75 .55 .73 1.14 .69
KLA/ATP .92 .94 .80 .64 .64 .83 .65
Ppp1cc
KLA  ATP  ATP+KLA
 NM_013636 protein phosphatase 1, catalytic subunit, gamma isoform (Ppp1cc), mRNA [NM_013636] KLA .51 .51 .49 .48 .53 .64 .64
ATP 1.02 1.01 .85 .79 .72 .89 .95
KLA/ATP .54 .49 .42 .43 .56 .76 .81
Ppp1r12a
KLA  ATP  ATP+KLA
 AK077739 8 days embryo whole body cDNA, RIKEN full-length enriched library, clone:5730577I22 product:inferred: myosin phosphatase, target subunit 1, full insert sequence [AK077739] KLA 1.91 1.98 2.00 2.00 1.63 1.58 1.17
ATP .93 .80 .82 .46 1.01 1.29 .79
KLA/ATP 1.82 1.80 1.85 .91 1.54 1.51 .90
Ppp1r12a
KLA  ATP  ATP+KLA
 NM_027892 protein phosphatase 1, regulatory (inhibitor) subunit 12A (Ppp1r12a), mRNA [NM_027892] KLA 2.36 2.42 2.34 2.71 1.96 2.11 1.93
ATP .87 .85 1.00 .98 1.75 4.57 2.89
KLA/ATP 2.02 2.24 2.59 1.90 2.16 4.01 5.77
Ppp1r12b
KLA  ATP  ATP+KLA
 AK132310 15 days embryo head cDNA, RIKEN full-length enriched library, clone:4022402N03 product:unclassifiable, full insert sequence [AK132310] KLA .82 .86 .71 .94 1.26 1.84 5.38
ATP 1.02 1.07 1.17 1.23 1.24 1.58 1.53
KLA/ATP .83 .82 .82 .84 .80 1.51 3.05
Ppp1r12b
KLA  ATP  ATP+KLA
 NM_001081307 protein phosphatase 1, regulatory (inhibitor) subunit 12B (Ppp1r12b), mRNA [NM_001081307] KLA .78 .80 .80 .75 .85 .79 .91
ATP .87 .83 .89 .75 1.01 .88 1.04
KLA/ATP .74 .73 .78 .71 .88 .86 .89
Prkca
KLA  ATP  ATP+KLA
 NM_011101 protein kinase C, alpha (Prkca), mRNA [NM_011101] KLA 1.00 .96 .94 .95 .95 .89 .96
ATP 1.00 1.03 .91 .94 .82 .87 1.13
KLA/ATP 1.02 .95 .91 .86 .78 .84 .94
Prkcb1
KLA  ATP  ATP+KLA
 NM_008855 protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855] KLA .92 .95 .93 .78 .77 1.08 1.83
ATP 1.03 1.12 1.09 1.23 .90 2.08 .96
KLA/ATP .98 .99 .82 .89 .62 1.01 1.08
Prkcc
KLA  ATP  ATP+KLA
 NM_011102 protein kinase C, gamma (Prkcc), mRNA [NM_011102] KLA 1.02 1.04 1.11 1.04 .96 1.02 1.05
ATP .98 .98 1.05 1.03 1.08 .96 .95
KLA/ATP 1.21 1.16 1.09 1.07 1.04 .98 .93
Pten
KLA  ATP  ATP+KLA
 NM_008960 phosphatase and tensin homolog (Pten), mRNA [NM_008960] KLA .79 .73 .61 .59 .56 .70 1.00
ATP 1.04 1.11 1.07 1.12 1.03 1.38 .83
KLA/ATP .75 .69 .60 .74 .93 1.09 1.24
Ptk2
KLA  ATP  ATP+KLA
 NM_007982 PTK2 protein tyrosine kinase 2 (Ptk2), mRNA [NM_007982] KLA .99 .99 1.02 1.04 1.09 1.22 1.57
ATP 1.04 1.09 .95 .98 .67 .96 .87
KLA/ATP .99 1.03 .87 .93 .81 1.16 1.04
Pxn
KLA  ATP  ATP+KLA
 AK084243 12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230012N01 product:inferred: paxillin beta {Homo sapiens}, full insert sequence. [AK084243] KLA 1.06 .92 1.01 .95 .97 .97 1.02
ATP 1.02 1.02 .97 .90 .98 .94 .89
KLA/ATP .96 .97 .98 .91 1.01 1.00 .94
Pxn
KLA  ATP  ATP+KLA
 NM_133915 paxillin (Pxn), transcript variant beta, mRNA [NM_133915] KLA 1.13 1.13 1.14 1.14 1.49 1.60 1.30
ATP 1.11 1.22 .86 1.04 1.14 1.18 1.35
KLA/ATP 1.41 1.22 .80 .92 1.07 1.54 2.60
Rac1
KLA  ATP  ATP+KLA
 NM_009007 RAS-related C3 botulinum substrate 1 (Rac1), mRNA [NM_009007] KLA 1.02 1.01 1.02 .99 1.03 1.15 1.08
ATP .99 1.15 1.01 1.27 1.06 1.20 1.06
KLA/ATP 1.00 1.04 .88 1.16 .91 1.21 1.38
Rac2
KLA  ATP  ATP+KLA
 NM_009008 RAS-related C3 botulinum substrate 2 (Rac2), mRNA [NM_009008] KLA 1.55 1.68 1.86 2.15 3.36 3.59 3.74
ATP 1.13 1.16 .74 .99 .84 .91 1.66
KLA/ATP 1.59 1.71 1.19 1.56 1.21 1.60 3.48
Rac3
KLA  ATP  ATP+KLA
 NM_133223 RAS-related C3 botulinum substrate 3 (Rac3), mRNA [NM_133223] KLA 2.03 2.20 2.64 2.18 2.95 2.29 1.41
ATP 1.02 1.12 .94 1.42 1.16 .84 .87
KLA/ATP 2.30 2.32 1.57 2.55 1.75 1.47 1.61
Raf1
KLA  ATP  ATP+KLA
 AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
 NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Rap1a
KLA  ATP  ATP+KLA
 AK030897 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830450G12 product:RAS-related protein-1a, full insert sequence [AK030897] KLA .83 .80 .92 1.04 1.06 .91 1.06
ATP 1.04 .92 1.11 1.03 1.05 .73 .72
KLA/ATP .83 .81 .97 .75 1.14 .71 .53
Rap1a
KLA  ATP  ATP+KLA
 NM_145541 RAS-related protein-1a (Rap1a), mRNA [NM_145541] KLA .87 .78 .76 .86 .86 .84 1.01
ATP .91 .95 1.33 1.20 1.27 1.04 .81
KLA/ATP .68 .75 .92 .85 1.13 .90 .74
Rap1b
KLA  ATP  ATP+KLA
 M79314 GTP-binding protein RAP1b mRNA, partial cds. [M79314] KLA 2.61 2.95 2.81 2.76 3.07 2.67 1.88
ATP 1.00 1.10 1.00 1.94 1.94 1.72 1.31
KLA/ATP 2.49 2.45 2.03 4.23 3.03 2.60 1.86
Rap1b
KLA  ATP  ATP+KLA
 NM_024457 RAS related protein 1b (Rap1b), mRNA [NM_024457] KLA 2.21 2.35 2.71 2.51 2.86 2.44 1.54
ATP 1.05 .92 .93 1.14 1.30 1.26 1.07
KLA/ATP 2.23 2.15 1.57 2.53 2.16 1.67 1.38
Rapgef1
KLA  ATP  ATP+KLA
 NM_001039087 Rap guanine nucleotide exchange factor (GEF) 1 (Rapgef1), transcript variant 1, mRNA [NM_001039087] KLA .93 .89 .88 .67 .73 .90 1.16
ATP 1.12 1.09 .82 1.25 1.43 1.63 1.58
KLA/ATP 1.03 .95 .67 .74 .65 .89 1.77
Rasgrf1
KLA  ATP  ATP+KLA
 BC042449 RAS protein-specific guanine nucleotide-releasing factor 1, mRNA (cDNA clone IMAGE:5367388), complete cds. [BC042449] KLA 1.11 1.11 1.10 1.14 1.10 1.07 1.16
ATP 1.03 1.14 1.26 1.35 1.09 1.10 1.01
KLA/ATP 1.12 1.14 1.13 1.15 .99 1.04 1.43
Rasgrf1
KLA  ATP  ATP+KLA
 NM_001039655 RAS protein-specific guanine nucleotide-releasing factor 1 (Rasgrf1), transcript variant 2, mRNA [NM_001039655] KLA 1.26 1.28 1.28 1.29 1.34 1.26 1.47
ATP 1.03 1.04 1.05 .92 .98 1.18 1.22
KLA/ATP 1.33 1.38 1.28 1.18 1.07 1.18 2.74
Rasgrf1
KLA  ATP  ATP+KLA
 NM_011245 RAS protein-specific guanine nucleotide-releasing factor 1 (Rasgrf1), transcript variant 1, mRNA [NM_011245] KLA 1.02 1.05 1.14 1.06 1.14 1.11 1.08
ATP 1.03 .99 1.00 .91 .94 .99 1.01
KLA/ATP 1.03 1.00 1.14 1.13 .98 1.01 1.53
Reln
KLA  ATP  ATP+KLA
 NM_011261 reelin (Reln), mRNA [NM_011261] KLA 1.00 1.00 .98 1.03 1.00 .99 .99
ATP 1.00 .99 1.05 1.08 1.01 .99 1.00
KLA/ATP 1.01 1.02 1.05 1.03 .98 .98 .98
Rhoa
KLA  ATP  ATP+KLA
 NM_016802 ras homolog gene family, member A (Rhoa), mRNA [NM_016802] KLA .93 1.00 1.07 .97 1.08 1.06 1.02
ATP .93 .88 .49 .61 .63 .78 1.05
KLA/ATP .94 .92 .59 .63 .61 .78 1.12
Rock1
KLA  ATP  ATP+KLA
 NM_009071 Rho-associated coiled-coil containing protein kinase 1 (Rock1), mRNA [NM_009071] KLA 2.40 2.48 2.37 3.07 1.94 1.42 1.21
ATP .95 .92 .87 .70 1.13 1.74 .98
KLA/ATP 2.27 2.35 2.56 1.60 1.65 1.56 1.23
Rock2
KLA  ATP  ATP+KLA
 NM_009072 Rho-associated coiled-coil containing protein kinase 2 (Rock2), mRNA [NM_009072] KLA .99 .92 .83 .87 .73 .74 1.04
ATP 1.07 1.31 1.16 1.02 1.02 1.03 .88
KLA/ATP 1.00 1.07 .93 .85 .69 .63 .81
Shc1
KLA  ATP  ATP+KLA
 NM_011368 src homology 2 domain-containing transforming protein C1 (Shc1), transcript variant 2, mRNA [NM_011368] KLA .88 .87 .86 .83 1.09 1.11 1.12
ATP 1.04 1.25 .85 1.17 .93 1.16 1.00
KLA/ATP .93 .96 .62 .96 .75 1.25 1.19
Shc2
KLA  ATP  ATP+KLA
 NM_001024539 src homology 2 domain-containing transforming protein C2 (Shc2), mRNA [NM_001024539] KLA 1.19 1.25 1.22 1.16 1.15 1.14 .98
ATP 1.04 1.14 1.15 1.53 1.29 1.06 1.09
KLA/ATP 1.26 1.24 1.26 1.49 1.31 1.30 1.30
Shc3
KLA  ATP  ATP+KLA
 NM_009167 src homology 2 domain-containing transforming protein C3 (Shc3), mRNA [NM_009167] KLA 1.00 .98 1.06 1.06 1.12 1.08 1.04
ATP .99 1.02 1.00 1.05 1.00 1.08 1.08
KLA/ATP 1.08 1.06 1.01 1.06 1.03 1.12 1.41
Shc4
KLA  ATP  ATP+KLA
 NM_199022 SHC (Src homology 2 domain containing) family, member 4 (Shc4), mRNA [NM_199022] KLA 1.03 1.03 1.01 1.06 1.09 1.03 1.06
ATP .99 1.00 1.03 1.02 1.04 1.04 1.01
KLA/ATP .98 .97 1.06 1.05 1.00 1.00 1.14
Sos1
KLA  ATP  ATP+KLA
 NM_009231 Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] KLA 2.36 2.40 3.42 3.15 2.78 1.81 1.71
ATP .99 1.00 .99 1.15 1.14 1.25 1.24
KLA/ATP 2.41 2.26 1.95 2.44 1.47 1.66 1.37
Sos2
KLA  ATP  ATP+KLA
 XM_127051 gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] KLA .81 .77 .79 .92 1.04 1.06 1.20
ATP 1.00 1.00 1.09 .79 .68 .81 .94
KLA/ATP .77 .69 .71 .60 .64 .77 1.07
Spp1
KLA  ATP  ATP+KLA
 NM_009263 secreted phosphoprotein 1 (Spp1), mRNA [NM_009263] KLA 1.41 1.62 1.39 1.31 1.31 1.00 .51
ATP 1.08 1.21 1.49 1.79 2.55 3.51 3.41
KLA/ATP 1.40 1.54 1.51 1.43 2.01 3.18 2.46
Src
KLA  ATP  ATP+KLA
 NM_009271 Rous sarcoma oncogene (Src), transcript variant 1, mRNA [NM_009271] KLA 6.99 7.23 7.54 5.99 5.34 3.39 3.00
ATP 1.02 1.06 1.06 2.08 4.41 5.03 3.97
KLA/ATP 7.44 7.51 5.48 6.24 4.86 5.86 7.90
Thbs1
KLA  ATP  ATP+KLA
 NM_011580 thrombospondin 1 (Thbs1), mRNA [NM_011580] KLA 2.22 2.22 2.74 3.10 4.57 7.17 7.22
ATP 1.16 2.53 8.45 12.26 15.50 43.06 35.83
KLA/ATP 2.46 3.43 8.29 17.50 28.16 46.17 54.67
Thbs2
KLA  ATP  ATP+KLA
 NM_011581 thrombospondin 2 (Thbs2), mRNA [NM_011581] KLA .99 1.03 1.04 1.03 1.04 1.17 1.03
ATP 1.01 1.04 1.01 1.02 .98 1.03 .97
KLA/ATP 1.08 1.04 .95 1.05 1.15 1.14 1.04
Thbs3
KLA  ATP  ATP+KLA
 NM_013691 thrombospondin 3 (Thbs3), mRNA [NM_013691] KLA .86 .93 .86 .95 .90 .79 .79
ATP 1.06 1.02 1.11 1.10 .96 1.03 1.07
KLA/ATP .90 .88 .92 .92 .98 .96 .98
Thbs4
KLA  ATP  ATP+KLA
 NM_011582 thrombospondin 4 (Thbs4), mRNA [NM_011582] KLA 1.16 1.13 1.19 1.13 1.13 1.16 1.07
ATP 1.00 1.14 1.07 .99 1.07 1.25 1.10
KLA/ATP 1.16 1.18 1.24 1.55 1.55 1.94 1.48
Tln1
KLA  ATP  ATP+KLA
 NM_011602 talin 1 (Tln1), mRNA [NM_011602] KLA .95 1.02 1.10 .90 1.30 1.13 .92
ATP 1.14 1.35 .60 .92 .76 .60 .89
KLA/ATP 1.21 1.18 .51 .77 .55 .70 1.20
Tln2
KLA  ATP  ATP+KLA
 NM_001081242 talin 2 (Tln2), mRNA [NM_001081242] KLA 1.03 1.01 .98 1.03 .96 .93 .94
ATP 1.01 .97 .98 1.00 .93 .87 .97
KLA/ATP 1.00 .99 1.03 .98 .87 .84 .89
Tnc
KLA  ATP  ATP+KLA
 AK048765 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230053B09 product:tenascin C, full insert sequence. [AK048765] KLA 1.22 1.24 1.38 1.04 .98 1.03 1.03
ATP 1.01 1.04 1.02 1.08 .99 1.04 1.04
KLA/ATP 1.28 1.36 1.19 1.05 1.03 1.06 1.04
Tnc
KLA  ATP  ATP+KLA
 NM_011607 tenascin C (Tnc), mRNA [NM_011607] KLA 1.41 1.56 1.78 1.51 1.60 1.33 1.01
ATP 1.05 1.05 1.05 1.18 1.03 1.24 1.11
KLA/ATP 1.46 1.74 1.63 1.64 1.29 1.26 1.12
Tnn
KLA  ATP  ATP+KLA
 NM_177839 tenascin N (Tnn), mRNA [NM_177839] KLA 1.62 1.81 1.88 1.81 1.51 1.28 1.02
ATP 1.00 1.12 1.10 1.04 1.05 1.18 1.02
KLA/ATP 1.79 1.82 1.73 1.57 1.32 1.13 1.12
Tnr
KLA  ATP  ATP+KLA
 NM_022312 tenascin R (Tnr), mRNA [NM_022312] KLA .98 .94 1.01 1.02 .96 .98 .94
ATP 1.08 .97 1.00 .95 1.01 .89 1.10
KLA/ATP .98 1.03 1.00 .97 .94 .91 1.03
Tnxb
KLA  ATP  ATP+KLA
 NM_031176 tenascin XB (Tnxb), mRNA [NM_031176] KLA 1.02 .95 1.00 .96 .97 .99 .98
ATP .99 1.02 1.00 1.02 1.00 .98 1.01
KLA/ATP .99 1.04 1.01 .95 .99 .95 .97
Vasp
KLA  ATP  ATP+KLA
 NM_009499 vasodilator-stimulated phosphoprotein (Vasp), mRNA [NM_009499] KLA 4.52 4.78 4.94 4.54 5.95 5.17 5.17
ATP 1.11 1.31 .93 1.41 1.48 1.45 1.14
KLA/ATP 4.65 5.51 4.13 5.08 2.96 2.18 4.11
Vav1
KLA  ATP  ATP+KLA
 NM_011691 vav 1 oncogene (Vav1), mRNA [NM_011691] KLA .79 .83 .98 1.17 1.97 2.42 2.26
ATP 1.06 1.02 .88 1.01 1.34 .82 1.36
KLA/ATP .88 .85 .73 .78 1.25 1.47 2.17
Vav2
KLA  ATP  ATP+KLA
 BC053060 vav 2 oncogene, mRNA (cDNA clone MGC:62363 IMAGE:5704852), complete cds [BC053060] KLA .73 .58 .55 1.16 .76 1.35 1.75
ATP .99 .89 .79 .82 .67 .85 1.09
KLA/ATP .64 .63 .61 .65 .66 .80 1.23
Vav2
KLA  ATP  ATP+KLA
 NM_009500 vav 2 oncogene (Vav2), mRNA [NM_009500] KLA .98 1.05 .98 .99 1.02 1.36 1.43
ATP 1.07 1.06 .96 1.01 .89 .95 1.08
KLA/ATP 1.04 1.05 .98 1.03 .88 .99 1.13
Vav3
KLA  ATP  ATP+KLA
 NM_020505 vav 3 oncogene (Vav3), transcript variant 1, mRNA [NM_020505] KLA .95 .94 .86 .87 .82 .66 .56
ATP 1.06 1.09 .81 1.05 .80 .75 .85
KLA/ATP 1.00 .84 .62 .85 .74 .56 .74
Vcl
KLA  ATP  ATP+KLA
 NM_009502 vinculin (Vcl), mRNA [NM_009502] KLA .88 .97 .87 .70 .73 .69 .70
ATP 1.07 1.25 1.00 1.24 .87 1.17 1.17
KLA/ATP .98 1.02 .72 .98 .58 .71 .88
Vegfa
KLA  ATP  ATP+KLA
 NM_001025250 vascular endothelial growth factor A (Vegfa), transcript variant 1, mRNA [NM_001025250] KLA .49 .48 .46 .46 .39 .64 1.18
ATP 1.05 1.37 3.82 10.55 12.51 24.20 7.85
KLA/ATP .48 .59 1.45 7.42 19.75 27.42 22.35
Vegfa
KLA  ATP  ATP+KLA
 NM_001025257 vascular endothelial growth factor A (Vegfa), transcript variant 3, mRNA [NM_001025257] KLA .72 .71 .66 .70 .65 .80 1.22
ATP 1.01 1.21 3.24 11.12 11.09 18.59 5.43
KLA/ATP .68 .71 1.47 5.94 15.06 20.32 17.31
Vegfb
KLA  ATP  ATP+KLA
 NM_011697 vascular endothelial growth factor B (Vegfb), mRNA [NM_011697] KLA .65 .63 .65 .63 .52 .38 .37
ATP 1.11 1.07 1.16 1.44 1.72 1.22 .43
KLA/ATP .67 .67 .89 .90 1.19 .86 .31
Vegfc
KLA  ATP  ATP+KLA
 NM_009506 vascular endothelial growth factor C (Vegfc), mRNA [NM_009506] KLA 2.07 2.21 2.04 3.27 2.51 1.73 2.90
ATP 1.08 1.03 1.24 1.32 2.55 5.18 2.58
KLA/ATP 2.20 2.29 2.72 2.97 4.35 4.24 5.06
Vtn
KLA  ATP  ATP+KLA
 NM_011707 vitronectin (Vtn), mRNA [NM_011707] KLA 1.05 1.05 1.01 1.00 .97 1.04 .95
ATP .94 .99 1.00 .94 .96 1.04 1.09
KLA/ATP .97 1.00 1.02 .99 .98 .94 .98
Vwf
KLA  ATP  ATP+KLA
 AK044921 9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130011O06 product:VON WILLEBRAND FACTOR (FRAGMENT) homolog [Saguinus bicolor], full insert sequence. [AK044921] KLA 1.02 .96 .97 .95 .97 1.00 .91
ATP 1.01 1.03 .93 1.02 1.01 1.00 1.08
KLA/ATP .99 .93 .99 .96 1.02 1.01 1.08
Vwf
KLA  ATP  ATP+KLA
 NM_011708 Von Willebrand factor homolog (Vwf), mRNA [NM_011708] KLA .56 .56 .51 .41 .37 .50 .33
ATP 1.09 .99 .77 .88 3.26 2.28 .64
KLA/ATP .65 .58 .46 .52 2.61 3.48 1.38
Xiap
KLA  ATP  ATP+KLA
 NM_009688 X-linked inhibitor of apoptosis (Xiap), mRNA [NM_009688] KLA 1.61 1.63 1.62 1.52 1.34 1.27 1.11
ATP 1.03 1.01 .99 .96 .88 1.19 1.25
KLA/ATP 1.64 1.63 1.54 1.33 1.08 1.19 1.72
Zyx
KLA  ATP  ATP+KLA
 NM_011777 zyxin (Zyx), mRNA [NM_011777] KLA 4.12 4.06 5.09 6.23 5.97 4.06 .71
ATP 1.06 .99 .81 .77 .94 2.67 1.54
KLA/ATP 4.64 4.37 4.67 4.65 3.76 3.47 2.09